Inhibrx Biosciences, Inc. (NASDAQ:INBX) is one of the best small cap stocks to buy for 10x potential.
Inhibrx Biosciences, Inc. (NASDAQ:INBX) announced on May 11 positive interim results from the randomized, first-line Phase 2 portion of the HexAgon study, with the trial evaluating the safety and efficacy of INBRX-106, a hexavalent OX40 agonist, in combination with pembrolizumab versus pembrolizumab monotherapy in first-line patients with treatment-naïve, PD-L1-positive metastatic or unresectable recurrent Head and Neck Squamous Cell Carcinoma
It reported that the interim analyses showed that INBRX-106 + pembrolizumab attained a 44.0% confirmed Objective Response Rate. In addition, the responding patients in the combination arm exhibited deeper overall tumor reductions, with the majority attaining target lesion shrinkage that exceeded 50%. Three patients also notably achieved a complete radiographic response.
In a separate development, Inhibrx Biosciences, Inc. (NASDAQ:INBX) received a rating update from Stifel on April 22. The firm lifted the price target on the stock to $300 from $150 and maintained a Buy rating on the shares. Inhibrx Biosciences, Inc. (NASDAQ:INBX) is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates that were developed through proprietary modular protein engineering platforms.